Poehling Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Poehling Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,000	Closed	-$25K	–	126
2022 Q3	$25K	Hold	16,000	–	–	0.01%	112
2022 Q2	$32K	Hold	16,000	–	–	0.01%	123
2022 Q1	$37K	Hold	16,000	–	–	0.01%	146
2021 Q4	$74K	Hold	16,000	–	–	0.02%	137
2021 Q3	$122K	Hold	16,000	–	–	0.04%	132
2021 Q2	$155K	Hold	16,000	–	–	0.05%	145
2021 Q1	$132K	Hold	16,000	–	–	0.05%	148
2020 Q4	$109K	Hold	16,000	–	–	0.04%	127
2020 Q3	$178K	Hold	16,000	–	–	0.09%	112
2020 Q2	$100K	Buy	+16,000	New	+$61.3K	0.05%	107

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Poehling Capital Management's SRNE Position: Q4 2022 in Review

Poehling Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 16,000 shares — an estimated $25K sold.

Poehling Capital Management first reported a position in SRNE in Q2 2020 and held it in 10 quarters. The position peaked at $178K in Q3 2020. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Poehling Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Poehling Capital Management sold 16,000 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $25K.
Poehling Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 10 quarters.
Poehling Capital Management's Sorrento Therapeutics, Inc. position peaked at $178K in Q3 2020.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Poehling Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.